Clinical trials: Metastatic Progressive Castration-resistant Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT05124795
- Testing
- IMU-935
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Immunic AG
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer.
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,
- Trial name
- PYRUS (NCT01692262)
- Testing
- Intermittent dosing of AZD5363
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Prostate Cancer
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior…
- Trial name
- NCT01414296
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Cancer of the Prostate, Metastatic Cancer
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer
- Trial name
- TheraP (NCT03392428)
- Testing
- 177Lu-PSMA617, Cabazitaxel
- Where
- 11 sites in Australia
- Volunteers
- 201 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Castration-Resistant Prostatic Cancer
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06033001
- Testing
- [Lu-177]-PNT2002
- Where
- 7 sites in United States
- Sponsor
- Lantheus Medical Imaging
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04033432
- Testing
- Recombinant EphB4-HSA Fusion Protein
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University